Financials Prediction Markets

FDA decision: Saroglitazar by Zydus Therapeutics (in 2026)
Yes
No
$1,842 vol
FDA decision: Lorundrostat by Mineralys Therapeutics (on or before December 22, 2026)
Yes
No
$70 vol
FDA decision: Ralinepag by United Therapeutics (on or before June 24, 2027)
Yes
No
$41 vol
FDA decision: Tozorakimab by AstraZeneca (on or before March 31, 2027)
Yes
No
$308 vol
FDA decision: Ulixacaltamide by Praxis Precision Medicines (on or before January 29, 2027)
Yes
No
$0 vol
FDA decision: Vamikibart by Genentech (on or before July 31, 2027)
Yes
No
$42 vol